Tasman Health Care | Oncology Research

Research site

Location

Suite 1 Level 3 123 Nerang St, Southport, Queensland, Australia

Site insights

Top conditions

Top treatments

Darolutamide

ERAS-254

Androgen

Radium-223 Dichloride

Aplitibart

Naporafenib

KIN-2787

Trametinib

Pembrolizumab

Avelumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

4 of 9 total trials

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2.Stage 2: To compare progression free survival (PFS) and over...

Enrolling

Advanced or Metastatic NRAS-mutant Melanoma

Drug: Trametinib

Drug: Naporafenib

Locations recently updated

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling

Biochemically Recurrent Prostate Cancer

Other: Placebo matching darolutamide

Drug: Darolutamide (BAY1841788, Nubeqa)

A Study to Evaluate KIN-2787 in Participants with BRAF And/or NRAS Mutation Positive Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Enrolling

Melanoma

Solid Tumor, Adult

Drug: KIN-2787 and binimetinib

Drug: KIN-2787

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participan...

Active, not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Drug: NAH therapy

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)